Trial Profile

A Phase 2 Proof-of-Concept Study to Evaluate Nolasiban in China

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nolasiban (Primary)
Indications Female infertility
Focus Proof of concept; Therapeutic Use
Sponsors Yuyuan BioScience Technology

Most Recent Events

13 Jul 2023 According to an ObsEva media release, the company announced that it has recovered full worldwide rights on nolasiban, following the termination of its sub-licensing agreement with Yuyuan BioScience.
01 Jul 2020 According to an ObsEva media release, Yuyuan has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration (NMPA).This submission represents the first milestone in the process to enable this study in China.
22 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com